Key clinical point: Atogepant showed safety and efficacy for migraine headache prevention in a phase 2/3 study.
Major finding: Migraine headache frequency fell by an average 3.55-4.23 days per month, compared with an average drop of 2.85 days with placebo.
Study details: A multicenter, phase 2/3 dose-ranging study with 834 U.S. patients.
Disclosures: The study was sponsored by Allergan, the company developing atogepant and ubrogepant. Dr. Dodick has been a consultant to Allergan and to several other drug companies.
REPORTING FROM AHS 2019